Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/338175
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampAntunes, Edson-
dc.typeArtigopt_BR
dc.titleBAY 41-2272 inhibits human T lymphocyte functionspt_BR
dc.contributor.authorCarvalho, Marina U.W.B.-
dc.contributor.authorVendramini, Paola-
dc.contributor.authorKubo, Christina Arslanian-
dc.contributor.authorSoreiro-Pereira, Paulo Vítor-
dc.contributor.authorAlbuquerque, Rafael Sales de-
dc.contributor.authorAntunes, Edson-
dc.contributor.authorCondino-Neto, Antonio-
dc.subjectLinfócitos Tpt_BR
dc.subject.otherlanguageT-Lymphocytespt_BR
dc.description.abstractBAY 41-2272 increases guanosine 3′, 5′-cyclic monophosphate (cGMP) levels by stimulating soluble guanylate cyclase (sGC). In this study, we evaluated the effect of BAY 41-2272 on human T lymphocyte functions. Pretreating T cells for 24 h with BAY 41-2272 at 3 μM and 30 μM, followed by activation with 90 nM phorbol myristate acetate (PMA), inhibited interferon-gamma (IFN-γ) production, with 3 μM and 30 μM BAY causing 16.5-fold and 12.1-fold inhibition, respectively, compared to PMA alone (p < 0.05, one-way ANOVA followed by Tukey’s test). We also observed suppressive effects on the expression of CD69, with 30 μM BAY causing 3.55-fold lower expression than PMA/ionomycin (p < 0.001 one-way ANOVA followed by Tukey’s test), and T-bet, with 30 μM BAY causing 1.47-fold lower expression than PMA/ionomycin (p < 0.05, one-way ANOVA test followed by Tukey’s test). Additionally, T lymphocyte proliferation was reduced 2.13-fold and 4.3-fold, respectively, by 3 μM BAY and 30 μM BAY compared to PMA/ionomycin (p < 0.01, p < 0.001, one-way ANOVA followed by Tukey’s test). BAY 41-2272 inhibits human T lymphocyte function and may be explored as an immunomodulatory drug in patients with autoimmune/inflammatory diseases and lymphoproliferative syndromespt_BR
dc.relation.ispartofInternational immunopharmacologypt_BR
dc.relation.ispartofabbreviationInt. immunopharmacol.pt_BR
dc.publisher.cityLondonpt_BR
dc.publisher.countryEstados Unidospt_BR
dc.publisherElsevierpt_BR
dc.date.issued2019-12-
dc.date.monthofcirculationDec.pt_BR
dc.language.isoengpt_BR
dc.description.volume77pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn1567-5769pt_BR
dc.identifier.eissn1878-1705pt_BR
dc.identifier.doi10.1016/j.intimp.2019.105976pt_BR
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S156757691930668Xpt_BR
dc.description.sponsorshipCOORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR - CAPESpt_BR
dc.description.sponsorshipFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPpt_BR
dc.description.sponsordocumentnumberNão tempt_BR
dc.description.sponsordocumentnumberNão tempt_BR
dc.date.available2020-03-30T19:30:20Z-
dc.date.accessioned2020-03-30T19:30:20Z-
dc.description.provenanceSubmitted by Susilene Barbosa da Silva (susilene@unicamp.br) on 2020-03-30T19:30:20Z No. of bitstreams: 0. Added 1 bitstream(s) on 2020-07-20T14:20:14Z : No. of bitstreams: 1 000503099100056.pdf: 1044675 bytes, checksum: e23cf6804a87c8bb5be74e0e68dcc5fb (MD5)en
dc.description.provenanceMade available in DSpace on 2020-03-30T19:30:20Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-12en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/338175-
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordBAY 41-2272pt_BR
dc.subject.keywordcGMPpt_BR
dc.subject.keywordsGCpt_BR
dc.identifier.source000503099100056pt_BR
dc.creator.orcid0000-0003-2201-8247pt_BR
dc.type.formArtigopt_BR
dc.identifier.articleid105976pt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000503099100056.pdf1.02 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.